Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

The effect of idursulfase on growth in patients with Hunter syndrome : data from the Hunter Outcome Survey (HOS) (CROSBI ID 201077)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Jones, S.A. ; Parini, R. ; Harmatz, P. ; Giugliani, R. ; Fang, J. ; Mendelsohn, N.J. ; ... ; Barić, Ivo ; Barišić, Ingeborg ; ... The effect of idursulfase on growth in patients with Hunter syndrome : data from the Hunter Outcome Survey (HOS) // Molecular genetics and metabolism, 109 (2013), 1; 41-48. doi: 10.1016/j.ymgme.2013.03.001

Podaci o odgovornosti

Jones, S.A. ; Parini, R. ; Harmatz, P. ; Giugliani, R. ; Fang, J. ; Mendelsohn, N.J. ; ... ; Barić, Ivo ; Barišić, Ingeborg ; ...

engleski

The effect of idursulfase on growth in patients with Hunter syndrome : data from the Hunter Outcome Survey (HOS)

Short stature is a prominent feature of this condition. This analysis aimed to investigate the effects of enzyme replacement therapy with idursulfase on growth in patients enrolled in HOS - the Hunter Outcome Survey which is a multinational observational database. As of Jan 2012, height data before treatment were available for 567 of 740 males followed prospectively after HOS entry. Cross-sectional analysis showed that short stature became apparent after approximately 8 years of age ; before this, height remained within the normal range. Age-corrected standardized height scores (z- scores) before and after treatment were assessed using piecewise regression model analysis in 133 patients (8-15 years of age at treatment start ; data available on ≥ 1 occasion within +/-24 months of treatment start ; growth hormone-treated patients excluded). Results showed that the slope after treatment (slope=-0.005) was significantly improved compared with before treatment (slope=-0.043) (difference=0.038, p=0.004). Analysis of covariates (age at treatment start, cognitive involvement, presence of puberty at the start of ERT, mutation type, functional classification), showed a significant influence on growth of mutation type (height deficit in terms of z-scores most pronounced in patients with deletions/large rearrangements/nonsense mutations, p<0.0001) and age (most pronounced in the 12-15-year group, p<0.0001). Cognitive involvement, pubertal status at the start of ERT and functional classification were not related to the growth deficit or response to treatment. In conclusion, the data showed an improvement in growth rate in patients with Hunter syndrome following idursulfase treatment.

Hunter syndrome; enzyme replacement therapy; growth; lysosomal storage disease; mucopolysaccharidosis type II; z-Score

HOS Natural History Working Group on behalf of HOS Investigators.

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

109 (1)

2013.

41-48

objavljeno

1096-7192

10.1016/j.ymgme.2013.03.001

Povezanost rada

nije evidentirano

Poveznice
Indeksiranost